GSK’s experimental drug, depemokimab, has demonstrated positive results in phase 3 trials for treating chronic rhinosinusitis with nasal polyps (CRSwNP). The drug successfully reduced polyp size and nasal obstruction in patients, indicating its potential as a new treatment option for this chronic condition.